Key result
GLP-1 receptor agonists and SGLT-2 inhibitors reduced MACE to a similar extent in patients with and without cardiovascular disease, but had differential effects on MI and stroke.
Why the study?
The differential effects of GLP-1 receptor agonists and SGLT-2 inhibitors on major adverse cardiovascular events in patients with and without cardiovascular disease were unclear.
Do GLP-1 receptor agonists and SGLT-2 inhibitors reduce MACE similarly in patients with and without cardiovascular disease?
Meta-Analysis
Do GLP-1 receptor agonists and SGLT-2 inhibitors reduce MACE similarly in patients with and without cardiovascular disease?
GLP1Ra and SGLT2i provide consistent MACE reduction regardless of baseline cardiovascular disease, though they have differential effects on MI and stroke.
Supports GLP-1RA/SGLT2i use for MACE reduction regardless of CVD history; confirms similar efficacy with differential MI versus stroke effects.
Glucagon-like peptide-1 receptor agonists (GLP1Ra) and sodium-glucose co-transporter-2 inhibitors (SGLT2i) reduce major adverse cardiovascular events (MACE). We assessed whether the effect differs in patients with and without cardiovascular (CV) disease, and rated the certainty of evidence by conducting a systematic review, meta-analysis, and trial sequential analysis of randomized controlled trials. Certainty of the evidence (CoE) was rated using the Grading of Recommendations, Assessment, Development, and Evaluation guidelines. The reduction in the risk of MACE was significant for both medications (high CoE), and the effect was similar in patients with and without CV disease (moderate CoE). GLP1Ra and SGLT2i reduced the risk of CV death (with high and moderate CoE, respectively), and the effects were consistent in the subgroups, but with very low CoE. While SGLT2i reduced the risk of fatal or non-fatal MI with a consistent effect in the subgroups, GLP1Ra reduced the risk of fatal or non-fatal stroke (with high CoE). In conclusion, GLP1Ra and SGLT2 inhibitors reduce the MACE to a similar extent in patients with and without CV disease, but have a differential effect on the reduction of fatal or non-fatal MI and stroke.
No takes yet. Share an insight, caveat, or question.
Kılıçkap et al. (2023) conducted a meta-analysis in Cardiovascular disease. GLP-1 Receptor Agonists and SGLT-2 Inhibitors was evaluated on Major adverse cardiovascular events (MACE). GLP-1 receptor agonists and SGLT-2 inhibitors reduced MACE to a similar extent in patients with and without cardiovascular disease, but had differential effects on MI and stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: